Publications by authors named "Emily S Chambers"

Claim this Profile
P
Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer.
Daniel P Bondeson, Brenton R Paolella, Adhana Asfaw, Michael V Rothberg, Thomas A Skipper, Emily S Chambers

Nat Cancer· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd.
Heidi M Haikala, Timothy Lopez, Jens Köhler, Pinar O Eser, Man Xu, Emily S Chambers

Cancer Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of -mutant lung cancer.
Pınar Özden Eser, Raymond M Paranal, Jieun Son, Elena Ivanova, Yanan Kuang, Emily S Chambers

Sci Transl Med· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ERK Inhibitor LY3214996-Based Treatment Strategies for -Driven Lung Cancer.
Jens Köhler, Yutong Zhao, Jiaqi Li, Prafulla C Gokhale, Hong L Tiv, Emily S Chambers

Mol Cancer Ther· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations.
Atsuko Ogino, Jihyun Choi, Mika Lin, Margaret K Wilkens, Antonio Calles, Emily S Chambers

Mol Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a RAS-activating Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung Cancer.
Alissa J Cooper, Yoshihisa Kobayashi, Dewey Kim, Sarah E Clifford, Sasha Kravets, Emily S Chambers

Clin Cancer Res· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for Mutant Non-Small Cell Lung Cancer.
Elena Ivanova, Mari Kuraguchi, Man Xu, Andrew J Portell, Luke Taus, Emily S Chambers

Clin Cancer Res· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers.
Stephanie L Guerra, Ophélia Maertens, Ryan Kuzmickas, Thomas De Raedt, Richard O Adeyemi, Emily S Chambers

Cancer Cell· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amplification of Wild-type Imparts Resistance to Crizotinib in Exon 14 Mutant Non-Small Cell Lung Cancer.
Magda Bahcall, Mark M Awad, Lynette M Sholl, Frederick H Wilson, Man Xu, Emily S Chambers

Clin Cancer Res· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients.
Mizuki Nishino, Nikhil H Ramaiya, Emily S Chambers, Anika E Adeni, Hiroto Hatabu

J Immunother Cancer· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer.
Mizuki Nishino, Emily S Chambers, Curtis R Chong, Nikhil H Ramaiya, Stacy W Gray

Cancer Immunol Res· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis